Women's Heart Advisor October 2007 Issue

The Risks and benefits of Glycoprotein IIa / IIIa Inhibitors

These drugs are used to treat possible heart attacks and to prevent clotting during angioplasty, but beware of bleeding risks.

Glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors are powerful medications that prevent platelets from sticking together and forming a clot. Different GPIIb/IIIa inhibitors—abciximab (ReoPro), eptifibatide (Integrilin), and tirofiban (Aggrastat)—are given intravenously before angioplasty or during a suspected heart attack. GPIIb/IIIa inhibitors have been shown to reduce the need for an urgent repeat revascularization, bypass surgery, heart attack or death within 30 days of the procedure in both men and women.

To continue reading this article you must be a paid subscriber.

Subscribe to Heart Advisor

Get the next year of HEART ADVISOR for just $20. That's a savings of $19 off the regular rate.

With your paid subscription you will receive unlimited access to all of our online content. That is over a decade of previous issues from Cleveland Clinic, the hospital rated #1 in cardiac care by U.S. News & World Report - free of charge.

Subscriber Log In

Forgot your password? Click Here.

Already subscribe but haven't registered for all the benefits of the website? Click here.